Finn Patrick John

TWST President/COO sells 68,967 shares for $3,562,416.57 in 4 transactions on 2026-02-17

Finn Patrick John, President and COO of Twist Bioscience, executed 4 separate sales totaling 68,967 shares for $3,562,416.57 on 2026-02-17, reducing his holdings by 19.3% to 287,788 shares. The sales occurred at prices ranging from $50.32 to $53.11, with a blended average of $51.65, against a current price of $52.49. At the same-ticker level, John's prior 4 trades at TWST show mixed timing outcomes—1 of 3 prior sells were well-timed at the 90-day mark—while his cross-ticker track record (4 prior sells across all tickers) averaged +4.8% over 90 days with a 33.33% well-timed rate, suggesting his sells have not consistently predicted downturns. The company remains unprofitable (net income of $-30,507,000.00 in the latest quarter) despite 20.3% annual revenue growth, and the stock has risen 83.8% over 90 days and 26.0% over 30 days, near its 52-week high of $54.92. The substantial sale size and dollar amount warrant investor attention given the timing relative to recent strong momentum.

Twist Bioscience COO Finn Patrick John sold 23,279 shares at $40.00 on 2026-01-13; stock up 32.6% over 30 days post-sale.

Finn Patrick John, President and COO, sold 23,279 shares at $40.00, reducing his holdings by -6.9% to 312,883 shares. The stock has appreciated 32.6% over the 30 days following the sale, and currently trades at $41.27, above the transaction price. His cross-ticker track record shows 3 prior sells with an average 90-day return of -9.6% and a 50.00% well-timed rate, indicating mixed timing performance. At TWST specifically, his prior two completed sells (2025-10-06 and 2025-05-08) produced a 90-day pattern of one well-timed outcome (negative return, -19.8% on 2025-05-08) and one neutral outcome (+0.6% on 2025-10-06). The company remains technically unprofitable on a full-year basis despite recent quarterly profitability and 20.3% annual revenue growth, trading at a P/E of 55.03. Post-transaction stock appreciation suggests this particular sale did not precede an anticipated decline.

TWST President/COO Finn Patrick John sold 17,606 shares at $31.44 on 2025-10-30; stock now at $31.57.

Finn Patrick John sold 17,606 shares of TWST at $31.44, representing a 6.1% reduction in holdings to 268,674 shares post-transaction. The stock has rallied 14.7% over 90 days and currently trades at $31.57, near the transaction price. His cross-ticker track record shows 2 prior sells with a 100.00% well-timed rate at the 90-day mark (average 90d return -19.8%), though his prior TWST sale on 2025-05-08 did underperform with a 90d return of -19.8%. The company reported revenue of $96,057,000 and net income of $20,390,000 in the latest quarter, growing 27.7% year-over-year, though it remains unprofitable on a full-year basis. The sale occurred shortly after another TWST sale on 2025-10-06, suggesting continued disposal activity over a concentrated period.

TWST President/COO Finn Patrick John sold 23,747 shares at $32.19; stock now -39.4% from 52-week high

Finn Patrick John (President and COO) sold 23,747 shares of Twist Bioscience at $32.19, reducing his holdings by 10.2% to 208,735 shares. The current price of $32.79 sits significantly below the 52-week high of $54.07 (down 39.4%), though up 24.9% over the past month. The timing context is notable: his prior TWST sale on 2025-05-08 was followed by a 90-day return of -19.8%, and his cross-ticker sell track record shows a 100.00% well-timed rate with average 90-day declines of 19.8%—suggesting a pattern of selling ahead of downturns. However, the company posted strong recent fundamentals with $96.1M in latest-quarter revenue, annual growth of 27.7%, and latest-quarter net income of $20.4M, despite being unprofitable on a full-year basis, leaving mixed signals about valuation and business momentum.

TWST President/COO Finn Patrick John sold 20,000 shares at $32.31; stock down 28.7% in 90 days amid unprofitability

Finn Patrick John, the President and COO of Twist Bioscience, sold 20,000 shares (20.0K shares) at $32.31 on 2025-05-08, reducing his stake from 262,660 shares to 242,660 shares. This sale occurs against a backdrop of material operational headwinds: the company reported net income of $-39.3M against revenue of $92.8M in the latest quarter, and remains unprofitable on a full-year basis despite posting 27.7% annual revenue growth. The stock has declined 28.7% over the past 90 days and currently trades 44.0% below its 52-week high of $58.88, suggesting the market has moved sharply against growth expectations. While the sale represents a 7.6% reduction in holdings, the C-suite executive retains a substantial 242.7K share position, and the absence of a designated trading plan FLAG permits observation that the timing—following significant price deterioration—warrants investor attention to whether deteriorating profitability or cash position is constraining executive conviction in near-term recovery.